NOVARTIS AG (NVS)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Annual

0 20B 40B 60B FY21: 42.8B FY22: 42.2B FY23: 45.4B FY24: 50.3B FY25: 54.5B FY21 FY22 FY23 FY24 FY25

Gross Profit Annual

0 15B 30B 45B FY21: 32.2B FY22: 31.9B FY23: 34.2B FY24: 38.9B FY25: 43B FY21 FY22 FY23 FY24 FY25

Operating Income Annual

0 6B 12B 18B FY21: 10.1B FY22: 7.9B FY23: 9.8B FY24: 14.5B FY25: 17.6B FY21 FY22 FY23 FY24 FY25

Net Income Annual

0 9B 18B 27B FY21: 24B FY22: 7B FY23: 14.9B FY24: 11.9B FY25: 14B FY21 FY22 FY23 FY24 FY25

Cost of Revenue Annual

0 5B 10B 15B FY21: 11.7B FY22: 11.6B FY23: 12.5B FY24: 12.8B FY25: 13.7B FY21 FY22 FY23 FY24 FY25

Operating Cash Flow Annual

0 7B 14B 21B FY21: 15.1B FY22: 14.2B FY23: 14.5B FY24: 17.6B FY25: 19.1B FY21 FY22 FY23 FY24 FY25

Free Cash Flow Annual

0 6B 12B 18B FY21: 14B FY22: 13.3B FY23: 13.4B FY24: 16.3B FY25: 17.6B FY21 FY22 FY23 FY24 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

EPS TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.